Jiangsu Yayao Biotech submitted the Investigational New Drug (IND) application for YY2201, an ATR Inhibitor, in China on June 28, 2024. This marks the first time a novel Category 1 drug from the company has reached the IND stage. According to the company's public information, the IND application for YY2201 is also underway in the USA. Yayao Biotech Logo YY2201 Yayo Biotech was founded by scientists who returned to China and local experts in the Pharmaceutical Valley of the Jiangbei New District in Nanjing. They prioritize the development of generic drugs, followed by novel drugs. Currently, their first p53-MDM2 inhibitor is in the process of being patented, although they already filed the first patent covering MDM2 inhibitors in 2021. In 2022, Yayao Biotech filed a patent (CN117247386) covering novel pyrazolopyrimidine compounds as ATR inhibitors with inventors XIAO Fei ( 肖飞 ), WENG Yali ( 翁亚丽 ), and WU Meng ( 吴萌 ) in China. The positive control drug is ceralasertib developed
China Biotech XYZ Shares Updates Related to New Drug Development in China